


PHARMACEUTICAL 2022

Evelo Biosciences Inc. Rank 430 of 475





PHARMACEUTICAL 2022

Evelo Biosciences Inc. Rank 430 of 475

The relative strengths and weaknesses of Evelo Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evelo Biosciences Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 122% points. The greatest weakness of Evelo Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 281% points.

The company's Economic Capital Ratio, given in the ranking table, is -582%, being 306% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	71,026
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,362
Liabilities, Non-Current	54,342
Other Assets	10,223
Other Compr. Net Income	0
Other Expenses	428
Other Liabilities	7,500
Other Net Income	-6,352
Property and Equipment	6,622
Research and Development	83,643
Revenues	0
Selling, General and Administrative Expense	31,753

Output Variable	Value in 1000 USD
Assets	87,871
Liabilities	79,204
Expenses	115,824
Stockholders Equity	8,667
Net Income	-122,176
Comprehensive Net Income	-122,176
Economic Capital Ratio	-582%